leisure time -WSS

leisure time

author：Wikipedia 2025-09-06 10:26:02 - browse：1

Kevin Sayer, CEO of Dexcom Dexcom

For years, diabetes tech company Dexcom has been striving to get its continuous glucose monitors into the hands of type 2 diabetes patients. Last week at the American Diabetes Association’s conference, the company unveiled plans for software built entirely for these patients, including ones who don’t take insulin.

“We’ve been so focused on things that match the needs of somebody who manages diabetes every minute of every day, and insulin delivery,” Kevin Sayer, CEO of Dexcom, told STAT. “This new product is going to be designed to address the needs of somebody with diabetes who’s not doing that, who has type 2 diabetes and is on other drugs.”

Continuous glucose monitoring is already well-established among people with type 1 diabetes, who rely on constant insulin therapy. The technology, which helps patients noninvasively monitor their blood sugar levels and control their insulin pump in real time, has grown rapidly in use over the years, culminating in a $5 billion market.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Liquid biopsy for lung cancer is launched by Delfi

focus

WSS

Addressing health care workers' trauma can help fight burnout

Bird flu surveillance in wastewater gets boost from consortium

VC firm General Catalyst wants to buy a health system

What to expect at HLTH 2023, the health care industry conference

Bill would stop addiction treatment from triggering child abuse inquiry

Investigation reveals sickle cell patients pressured into sterilizations

focus

leisure time

hotspot

Supreme Court strikes down use of affirmative action

A Q&A with the global head of Boehringer Ingelheim's innovation unit

Supreme Court strikes down use of affirmative action

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

In Memoriam: Notable people who died in 2023

Study finds gene variants tied to breast cancer risk in Black women

Medical leaders decry Supreme Court decision on affirmative action

3 questions for the future of Biden's cancer moonshot

Alkermes shareholders re

Phenylephrine and the overlooked value of the placebo effect

focus

Sana to lay off nearly a third of staff, de

Study finds gene variants tied to breast cancer risk in Black women

FDA poised to publish guidelines for clinical trial diversity

3 questions for the future of Biden's cancer moonshot

Stroke deaths set to near 10 million globally by 2050

Readout Newsletter: Eli Lilly, AstraZeneca, Bristol Meyers Squibb

leisure time

leisure time

focus

hotspot